Will precision medicine help tailor dyslipidemia treatment?
EAS Academy, Alberto Zambon, 200946
Can we refine strategy on HDL by new pharmacological approaches?
EAS Academy, John M. Chapman, 200945
Identification of novel targets in Hypertension and priorities for drug development
EAS Academy, David Rosenbaum, 200944
Nutrigenomics for prevention and treatment of obesity
EAS Academy, Judith Aron-Wisnewsky, 200942
Is there a role for Advanced Atherosclerosis Imaging in targeted cardiovascular therapy?
EAS Academy, Erik Stroes, 200941
Do Novel Biomarkers improve cardiovascular risk stratification?
EAS Academy, Arnold von Eckardstein, 200940
Human Genetics from validation of novel cardiovascular drug targets to molecular diagnosis
EAS Academy, Alain Carrié, 200939
Precision Cardiovascular Medicine: an unmet need or just a fashion?
EAS Academy, Eran Leitersdorf, 200938
News from ESC: the REVEAL trial
EAS Academy, Alberico Catapano, 193805
News from ESC: the CANTOS trial
EAS Academy, Alberico Catapano, 196302
News from ESC: an update from the FOURIER study
EAS Academy, Alberico Catapano, 196303
An introduction to Familial Hypercholesterolaemia for clinicians
EAS Academy, Stefano Romeo, 183923
Treatment of FH: Diet, statin and statin intolerance
EAS Academy, Olov Wiklund, 183924
FH in children
EAS Academy, Albert Wiegman, 183925
Proprotein convertase subtilisin/kexin type 9 inhibitors
EAS Academy, Ulf Landmesser, 183926
Brown adipose tissue: a novel target to comBAT cardiometabolic disease
EAS Academy, Patrick C.N. Rensen, 175540
Circadian control of metabolism
EAS Academy, Frank A.J.L. Scheer, 175539
Importance of physical activity in metabolic and cardiovascular health and the influence of obesity and diabetes
EAS Academy, Patrick Schrauwen, 175538
Microbiome and cardiometabolic disease
EAS Academy, Fredrik Bäckhed, 175537
Diet and cardiometabolic health
EAS Academy, Qi Sun, 175536
Large-scale epidemiology assessment of the main determinants of cardiovascular disease
EAS Academy, Sarah Lewington, 175535
Mechanistic insights into innovative therapeutics in lipid lowering in vivo
EAS Academy, Henry Ginsberg, 175534
Temporal versus one-time biomarker measurements
EAS Academy, Lind Lars, 175530
Circulating miRNA for cardiovascular death prediction
EAS Academy, Tanja Zeller, 175529
Typical clinical cases: who may benefit?
EAS Academy, Eric Bruckert, 175527
The clinical evidence: Meta-analysis of the RCT
EAS Academy, Matteo Pirro, 175526
Updates on the guidelines. Which role for nutraceuticals?
EAS Academy, Emilio Ros, 175525
PET/MRI
EAS Academy, Marc Dweck, 175524
CT angiography
EAS Academy, Jason M. Tarkin, 175523
3D ultrasound
EAS Academy, Stephen Nicholls, 175522
Introduction to Detecting plaque burden or vulnerable plaque: Which way should we go?
EAS Academy, Lale Tokgözoglu, 176682
Demystifying the management of hypertrighceridemia
EAS Academy, Anne Tybjaerg-Hansen, 175521
Hepatic lipid and lipoprotein metabolism
EAS Academy, Marja-Riitta Taskinen, 175520
Regulation of lipid mobilization and lipoprotein secretion by the intestine
EAS Academy, Gary Lewis, 175519
How to treat diabetic dyslipidaemia: Introduction
EAS Academy, Borge Nordestgaard, 175531
How to treat diabetic dyslipidaemia
EAS Academy, Gerald Watts, 175532
How to treat diabetic dyslipidaemia
EAS Academy, Alberto Zambon, 175533
Balancing the fat: lipid droplets and human disease
EAS Academy, Robert Farese, Jr, 175518
How LDL causes inflammation in the artery wall
EAS Academy, Goran Hansson, 175517
HDL-cholesterol and cardiovascular disease: rethinking our approach
EAS Academy, John M. Chapman, 175516
Hypertriglyceridaemia: ApoC-III and ANGPTL3
EAS Academy, Sotirios Tsimikas, 175515
CVD prevention strategies: Discussion
EAS Academy, Session Speakers, 176681
Combination therapy a better way to treat?
EAS Academy, Lale Tokgözoglu, 175514
The value of generic medicines
EAS Academy, Gianni Corrao, 175513
DISCUSSION: What do FOURIER data mean for clinical practice?
EAS Academy, Session Speakers, 175508
Atherosclerosis regression: linking GLAGOV and FOURIER
EAS Academy, Stephen Nicholls, 175507
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?: Discussion
EAS Academy, Session Speakers, 176676
LAL deficiency: Discussion
EAS Academy, Session Speakers, 176678
Fibrates in the management of AD and CVD risk
EAS Academy, Michal Vrablik, 175512
Enzymatic replacement therapy for lysosomal adic lipase deficiency in adult patients with lysosomal acid lipase deficiency
EAS Academy, Reena Sharma, 175510
FOURIER: first outcomes data with a PCSK9 inhibitor
EAS Academy, Terje R Pedersen, 175506
Atherogenic dyslipidemia (AD)
EAS Academy, Alberto Zambon, 175511
LDL is causal to atherosclerosis
EAS Academy, John M. Chapman, 175505
Lysosomal acid lipase deficiency - an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfunction
EAS Academy, Maurizio Averna, 175509
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?: Introduction
EAS Academy, Kausik Ray, 176674
Chronic kidney disease
EAS Academy, Alexandros Tselepis, 175502
Familial hypercholesterolaemia
EAS Academy, Kausik Ray, 175500
Primary prevention
EAS Academy, Guy De Backer, 175499
Secondary prevention
EAS Academy, Renata Cifkova, 175498
Prognostics in patients with manifest (acute or chronic) CHD
EAS Academy, Thomas F. Luscher, 175504
Summary and introduction of guidelines
EAS Academy, Alberico Catapano, 175497
Using naturally randomized genetic evidence to understand heritability of coronary artery disease?
EAS Academy, Brian Ference, 175503
Lowering LDL-C for cardiovascular disease
EAS Academy, Chris Packard, 175496
The case for immune cells: An expanded cardiovascular continuum
EAS Academy, Peter Libby, 175495
Innate immune response drives atherosclerosis
EAS Academy, Mihai Netea, 175494
Role of non-coding RNA for cholesterol homeostasis and atherogenesis
EAS Academy, Kathryn Moore, 175493
Anitschkow Lecture: Hematopoiesis, cholesterol and atherosclerosis
EAS Academy, Alan Tall, 175492
Introduction to Anitschkow prize winner
EAS Academy, Lale Tokgözoglu, 176670
Progress in understanding the role of nutrition in prevention of atherosclerosis: Discussion
EAS Academy, Session Speakers, 176669
The new EAS/ESC Guidelines on diet and lifestyle in cardiovascular prevention
EAS Academy, Gabriele Riccardi, 175491
Nordic and Mediterranean diet patterns from the CVD point of view
EAS Academy, Ursula Schwab, 175490
Life time exposure to LDL-cholesterol is it the key to CVD risk?
EAS Academy, Brian Ference, 175489
Progress in understanding the role of nutrition in prevention of atherosclerosis: Chair
EAS Academy, Jan Boren, 176668
Closing remarks
EAS Academy, Alberico Catapano, 175488
Clinical Cases Discussion
EAS Academy, Session Speakers, 175487
PCSK9 Inhibition: HIGHLIGHTS FROM RECENT PUBLICATIONS
EAS Academy, Alberico Catapano, 175486
Combination Therapy with non-Statin lipid lowering therapies
EAS Academy, Stephen Nicholls, 175485
Lipid lowering therapies: statins
EAS Academy, Stephen Nicholls, 175484
HDL, non HDL cholesterol and TG: a role in atherosclerosis?
EAS Academy, Kausik Ray, 175483
Plasma lipoproteins and their role in atherogenesis
EAS Academy, Jan Boren, 175482
Familial hypercholesterolemia detection and treatment and the EAS Initiatives
EAS Academy, Kausik Ray, 175481
Panel discussion
EAS Academy, Session Speakers, 175549
Genetics for the identification of therapeutic targets in dyslipidaemia
EAS Academy, Brian Ference, 175480
CVD: Epidemiology of the risk factors: the central role of LDL cholesterol
EAS Academy, Lale Tokgözoglu, 175479
Lipid guidelines, where we stand?
EAS Academy, Alberico Catapano, 175478
PCSK9 inhibitor therapy - The cure for atherosclerosis?
EAS Academy, Frederick Raal, 175476
PCSK9: From promise to clinical practice
EAS Academy, Gilles Lambert, 175475
Epidemiology of dyslipidemias focus on the region
EAS Academy, Hung-I Yeh, 175474
Introduction to the course
EAS Academy, Alberico Catapano, 175473
Cases and questions to illustrate the EAS/ESC dyslipidaemia guidelines 2016
EAS Academy, Session Speakers, 166915
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The new lipid Guidelines
EAS Academy, Alberico Catapano, 164450
2016 ESC/EAS Guidelines on the Management of Dyslipidaemias: Part 1
EAS Academy, Lale Tokgözoglu, 164451
PLASMA LIPIDOMIC PROFILES IMPROVE UPON CONVENTIONAL RISK FACTORS TO PREDICT CARDIOVASCULAR EVENTS
EAS Academy, Peter Meikle, 136740
CIRCULATING MICRORNA-122 IS ASSOCIATED WITH INCIDENT METABOLIC SYNDROME AND TYPE-2 DIABETES
EAS Academy, Peter Willeit, 136738
POPULATION APPROACH TO PREVENT CVD
EAS Academy, Eva Bossano Prescott, 136745
LIPIDS: WHAT IS NEW?
EAS Academy, Alberico Catapano, 136744
CIRCULATING CELLS AND CVD RISK
EAS Academy, Gerard Pasterkamp, 136737
WHAT ARE THE RISK FACTOR TARGETS?
EAS Academy, Ian Graham, 136743
HOW CAN WE IDENTIFY HIGH RISK?
EAS Academy, Ian Graham, 136742
INTRODUCTION: WHAT IS NEW IN THESE GUIDELINES?
EAS Academy, Olov Wiklund, 136741